|
|
Article: -GELTEX PHARMACEUTICALS: GelTex, Genzyme -- positive preliminary results of RenaGel clinical trial
- Article from:
- M2 Presswire
- Article date:
- June 30, 1998
CopyrightCOPYRIGHT 1998 Normans Media Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
M2 PRESSWIRE-30 June 1998-GELTEX PHARMACEUTICALS: GelTex Pharmaceuticals and Genzyme report positive preliminary results of extended use clinical trial of RenaGel non-absorbed phosphate binder (C)1994-98 M2 COMMUNICATIONS LTD RDATE:290698 -- RenaGel program updated at Cruttenden Roth financial conference GelTex Pharmaceuticals (Nasdaq: GELX) and Genzyme General (Nasdaq: GENZ) announced that preliminary results from an extended use, open-label study of RenaGel non-absorbed phosphate binder demonstrate RenaGel's ability to provide control of elevated serum phosphorus levels up to one year in chronic kidney failure patients without increasing serum calcium. GelTex made the ...
Related newspaper, magazine, and journal articles:
|
|
Article: GelTex Pharmaceuticals Reports Positive Results ...
PR Newswire;
March 10, 1997 ;
700+ words
... ... March 10 /PRNewswire/ -- GelTex Pharmaceuticals, Inc. (Nasdaq: GELX) today ... added that GelTex announced positive preliminary results from the first Phase III clinical ... Company recently announced encouraging preliminary results from two Phase II studies for CholestaGel ...
|
|